

Acceptance form regarding the public offer from Amgen to the shareholders of Nuevolution

Acceptance period: June 13, 2019 – July 4, 2019

The acceptance form shall be received by SEB Emissioner ("SEB") **no later than 17.00 (CEST) on July 4, 2019**. The acceptance form may be sent by mail, to SEB Emissioner AB03, SE-106 40 Stockholm, Sweden. The acceptance form may also be sent by email to emissioner@seb.se. The acceptance form should be sent or delivered in ample time prior to July 4, 2019.

Amgen Inc. ("**Amgen**") offers the shareholders in Nuevolution AB (publ) ("**Nuevolution**") to tender all of their shares in Nuevolution to Amgen for cash payment according to the complete terms and conditions set out in the offer document published June 12, 2019 (the "**Offer**" and the "**Offer Document**", respectively).

Amgen offers SEK 32.50 in cash for each share in Nuevolution. If Nuevolution pays dividends or makes any other distributions to shareholders, for which the record date occurs prior to the settlement of the Offer, the offer price will be reduced accordingly. No commission will be charged in connection with the Offer.

I / we hereby tender, in accordance with the terms and conditions set out in the Offer Document, the following shares in Nuevolution:

	shares in Nuevolution, registered on VP/service account: _____
--	---

If the number of shares in Nuevolution as stated above is incorrect, please change to the correct number. No further supplements or amendments may be made in the pre-printed text on the acceptance form.

If the above VP-account is a so-called transfer account, your bank must be contacted and asked to re-register it as soon as possible.

If the shares are pledged, the section below, which requests information pertaining to the pledgee, must be duly completed and signed by the pledgee. Incomplete or incorrect acceptance forms may be disregarded. The settlement amount will be paid to the yield account that is connected to the shareholder's securities account. Shareholders of Nuevolution who do not have a yield account connected to their securities account or whose yield account is a bank giro or postal giro account will receive the settlement amount in accordance with the instructions on the transaction note.

Completion of the Offer is conditional upon the conditions set out in the Offer Document. For complete terms and conditions, please see the Offer Document and the press release regarding the announcement of the Offer.

By signing this acceptance form I / we hereby instruct and empower SEB for my/our behalf to tender the above stated shares in Nuevolution according to the terms and conditions set out in the Offer Document and that I/we have read the Offer Document and read and understood the statements overleaf under "Important information".

Information regarding the holder

Address for transaction note will be obtained from Euroclear Sweden

Registration number	Daytime phone
Name	
Place	Date
The registered shareholder's signature (if applicable the representative / custodian)	
Please indicate LEI	

Information regarding the pledgee

(to be completed if the shares are pledged)

Personal ID number / Registration number	Daytime phone
Name / Company name	
Mailing address (street, box, etc)	
Postal code	City
Place	Date
Signature of pledgee	

Observe! If you are a representative, please fill in the information on page 2. →

Observe! See restrictions of excluded jurisdictions on page 2.

Information regarding the representative

(if applicable)

Personal ID number / Registration number	Daytime phone
Name / Company name	
Mailing address (street, box, etc)	
Postal code	City
Citizenship / LEI (Corporate)	Date
Signature of representative	

Important information

The Offer, pursuant to the terms and conditions presented in the Offer Document, is not being made to persons whose participation in the Offer requires that any additional offer document be prepared or registration effected or that any other measures be taken in addition to those required under Swedish law.

The distribution of the Offer Document, this acceptance form and any related offer documentation may in certain jurisdictions, including but not limited to Australia, Canada, Hong Kong, Japan, New Zealand and South Africa, be restricted or affected by the laws of such jurisdictions. Accordingly, copies of the Offer Document and this acceptance form are not being, and must not be, mailed or otherwise forwarded, distributed or sent in, into or from any such jurisdiction. Therefore, persons who receive the Offer Document and this acceptance form (including, without limitation, nominees, trustees and custodians) and are subject to the laws of any such jurisdiction will need to inform themselves about, and observe, any applicable restrictions or requirements. Any failure to do so may constitute a violation of the securities laws of any such jurisdiction. To the fullest extent permitted by applicable law, Amgen disclaims any responsibility or liability for the violation of any such restrictions by any person.

The Offer is not being made, and the Offer Document and this acceptance form may not be distributed, directly or indirectly, in or into, nor will any tender of shares be accepted from or on behalf of holders in, any jurisdiction in which the making of the Offer, the distribution of the Offer Document or the acceptance form, or the acceptance of any tender of shares would contravene applicable laws or regulations or require that further offer documents be prepared or that registration be effected, or other measures be taken, in addition to those required under Swedish law. By signing this acceptance form I/we hereby certify that I/we am/are not an Australian, Canadian, Hong Kong, Japanese, New Zealand or South African person, am/are not located in Australia, Canada, Hong Kong, Japan, New Zealand or South Africa and do not participate in such Offer from Australia, Canada, Hong Kong, Japan, New Zealand or South Africa and that I/we am/are not acting on a non-discretionary basis for a principal that is an Australian, Canadian, Hong Kong, Japanese, New Zealand or South African person, that is located in Australia, Canada, Hong Kong, Japan, New Zealand or South Africa or that is giving an order to participate in such offer from Australia, Canada, Hong Kong, Japan, New Zealand or South Africa.

The Offer, as well as the agreements entered into between Amgen and the Nuevolution shareholders as a result of the Offer, shall be governed and construed in accordance with substantive Swedish law. Any dispute regarding the Offer, or which arises in connection therewith, shall be exclusively settled by Swedish courts, and the City Court of Stockholm (Sw. Stockholms tingsrätt) shall be the court of first instance.